Felis ISSN 2398-2950

Methotrexate

Contributor(s): William Brewer Jr, Laura Garrett

Introduction

Name

  • Methotrexate.

Class of drug

  • Antimetabolite antineoplastic agent.

Description

Storage requirements

  • Room temperature.
  • Reconstituted powder stable for 4 weeks at room temperature and for 3 months under refrigeration when diluted to 2-25 mg/ml.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Lymphomas   Lymphoma  and some solid tumors.
  • This may be limited by its toxicity when used in a high dose regimen.
  • In human medicine it is also used to treat refractory rheumatoid arthritis.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Chloramphenicol, oral anticoagulants, phenylbutazone, phenytoin, salicylates, sulfonamides and tetracycline
  • Methotrexate is highly bound to serum albumin and thus may be displaced, resulting in increased blood levels and toxicity.

Folic acid supplements

  • May inhibit the response to methotrexate.

Pyrimethamine

  • A similar folic acid antagonist, may increase methotrexate toxicity.

Cytarabine

  • Increased cytotoxicity.

Hydrocortisone, hydroxyurea, methylprednisolone

  • Cellular uptake of methotrexate decreased.

Amphotericin B, vincristine

  • Cellular uptake of methotrexate increased.

NSAIDs

  • Increased risk of hematologic, renal and hepatic toxicity.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Other sources of information

  • Fischer D S, Knobf M Tet al(2003)The Cancer Chemotherapy Handbook.6th edn. Philadelphia, PA, Mosby. pp 167-171.
  • Based onSmall Animal Formulary.Tennant, Bryn (1999) 3rd edn. Cheltenham: BSAVA.
  • Plumb D (1999)Veterinary Drug Handbook.3rd Edn. Iowa State University Press.
  • Fraizier D L & Hahn K A (1995)Commonly Used Drugs.In: Hahn K A & Richardson R C (eds)Cancer Chemotherapy A Veterinary Handbook. Philadelphia, PA. Williams & Wilkins. pp 112-113.

ADDED